E-mail this page: News Release

Savient Announces Named Patient Programme for KRYSTEXXA® in the European Union for Patients with Refractory Chronic Gout

To (e-mail address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your e-mail address:   Copy yourself These e-mail addresses will be used to e-mail the page on your behalf and will not be used by Savient Pharmaceuticals for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps Savient Pharmaceuticals prevent automated submissions.